comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 09:03:24 - browse：442

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： What do new weight loss drugs mean for bariatric surgery?

focus

WSS

2024 GOP presidential candidates spar over abortion in debate

Kenai launches with $82 million for Parkinson’s stem cell therapy

FDA does about

2024 GOP presidential candidates spar over abortion in debate

Kenai launches with $82 million for Parkinson’s stem cell therapy

Medicare explains how it will choose drugs for negotiation

leisure time

comprehensive

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Flu vaccine offering decent levels of protection this winter, new data show

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

AstraZeneca bets AAV gene therapy will still deliver the goods

Guidelines to prevent youth baseball injuries need more muscle

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Alkermes shareholders re

Feds fine Medicare Advantage plans for overcharging members

Guidelines to prevent youth baseball injuries need more muscle

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

focus

Obesity now affects over 1 billion people worldwide, study finds

Departing Stanford president retracts two papers

Why more medical students aren't specializing in primary care

Why getting cancer drugs just got harder for rural patients

An inside look at PIPEs, biotech's buzzy new financing tool

Departing Stanford president retracts two papers

leisure time

entertainment

focus

explore